The IFNGR1 Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal cell population derived from A-549 human lung adenocarcinoma cells, featuring targeted disruption of the IFNGR1 gene. This polyclonal knockout eliminates functional interferon-gamma receptor 1 (IFNGR1) protein expression, providing a loss-of-function model for dissecting type II interferon signaling in lung cancer research.
The parental A-549 cell line was isolated from lung adenocarcinoma tissue of a 58-year-old male and is widely used as a model for non-small cell lung carcinoma, especially adenocarcinoma. These cells exhibit characteristics of alveolar type II pneumocytes and serve as a robust platform for cancer biology, drug response, and host?Cpathogen interaction studies.
IFNGR1 encodes the ligand-binding alpha chain of the IFN-?? receptor, which initiates the JAK-STAT signaling cascade. Upon IFN-?? binding, IFNGR1 dimerizes with IFNGR2, activating JAK1 and JAK2. These kinases phosphorylate STAT1, which dimerizes and translocates to the nucleus to bind gamma-activated sequence (GAS) elements. This drives transcription of IRF1 and CIITA, which in turn induce expression of MHC class I and II molecules, chemokines CXCL9, CXCL10, and CXCL11, iNOS, and PD-L1. Upstream regulators include IL-12, IL-18, and TCR signaling, which modulate cellular sensitivity to IFN-??.
In A-549 cells, knockout of IFNGR1 abolishes IFN-?? signal transduction, causing loss of JAK-STAT pathway activity. This prevents upregulation of antigen-presenting machinery and secretion of pro-inflammatory chemokines, mirroring IFN-?? insensitivity seen in immune-evasive tumors. Thus, these polyclonal knockout cells provide a relevant system to study contributions of IFN-?? signaling defects to immune escape, inflammation modulation, and therapy resistance in the lung microenvironment.
These polyclonal knockout cells are ideal for dissecting IFN-?? signaling in adenocarcinoma, validating immune checkpoint regulation, and co-culture assays modeling the tumor microenvironment. Validation assays include Western blot for phosphorylated STAT1, RT-qPCR for IRF1 and CXCL10, and flow cytometry for MHC class I and II. The cells also support high-throughput screening of pathway modulators, RNA-seq profiling, CXCL10 ELISA, and apoptosis or proliferation studies. For further details, please contact Ascent Research.
